Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxian Fengdian Wan is a traditional Chinese medicine (TCM) multi-herb formulation developed and manufactured by Tianjin Pharmaceutical Da Ren Tang. It is an oral medication indicated for the treatment of epilepsy and seizure disorders, specifically those categorized in TCM as being caused by "wind-phlegm blocking the orifices." The formulation typically includes a complex mixture of herbal, mineral, and animal-derived ingredients such as Realgar (雄黄), Hematite (赭石), Magnetite (磁石), Pinellia (半夏), Arisaema cum Bile (胆南星), Centipede (蜈蚣), and Scorpion (全蝎). These components work synergistically to clear phlegm, open sensory orifices, and calm the spirit (Shen), thereby addressing symptoms like sudden loss of consciousness, convulsions, and foaming at the mouth. As a traditional formulation, it does not have a single defined molecular target but is recognized in China as an approved pharmaceutical product for managing epileptic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangxian Fengdian Wan.